Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia

A Children's Oncology Group Study

I. Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie Gastier-Foster, Walker Wharton, Huining Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carroll, Meenakshi Devidas, D. Jeanette Pullen, Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W. Paul Bowman, William L. Carroll, Mignon L. Loh, Naomi J. Winick & 2 others Stephen P. Hunger, Cheryl L. Willman

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HRALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.

Original languageEnglish (US)
Pages (from-to)3512-3522
Number of pages11
JournalBlood
Volume119
Issue number15
DOIs
StatePublished - Apr 12 2012

Fingerprint

Pediatrics
Oncology
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sequence Deletion
Recurrence
Survival
Multivariate Analysis
Genes
Messenger RNA
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Chen, I. M., Harvey, R. C., Mullighan, C. G., Gastier-Foster, J., Wharton, W., Kang, H., ... Willman, C. L. (2012). Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study. Blood, 119(15), 3512-3522. https://doi.org/10.1182/blood-2011-11-394221

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia : A Children's Oncology Group Study. / Chen, I. Ming; Harvey, Richard C.; Mullighan, Charles G.; Gastier-Foster, Julie; Wharton, Walker; Kang, Huining; Borowitz, Michael J.; Camitta, Bruce M.; Carroll, Andrew J.; Devidas, Meenakshi; Pullen, D. Jeanette; Payne-Turner, Debbie; Tasian, Sarah K.; Reshmi, Shalini; Cottrell, Catherine E.; Reaman, Gregory H.; Bowman, W. Paul; Carroll, William L.; Loh, Mignon L.; Winick, Naomi J.; Hunger, Stephen P.; Willman, Cheryl L.

In: Blood, Vol. 119, No. 15, 12.04.2012, p. 3512-3522.

Research output: Contribution to journalArticle

Chen, IM, Harvey, RC, Mullighan, CG, Gastier-Foster, J, Wharton, W, Kang, H, Borowitz, MJ, Camitta, BM, Carroll, AJ, Devidas, M, Pullen, DJ, Payne-Turner, D, Tasian, SK, Reshmi, S, Cottrell, CE, Reaman, GH, Bowman, WP, Carroll, WL, Loh, ML, Winick, NJ, Hunger, SP & Willman, CL 2012, 'Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study', Blood, vol. 119, no. 15, pp. 3512-3522. https://doi.org/10.1182/blood-2011-11-394221
Chen, I. Ming ; Harvey, Richard C. ; Mullighan, Charles G. ; Gastier-Foster, Julie ; Wharton, Walker ; Kang, Huining ; Borowitz, Michael J. ; Camitta, Bruce M. ; Carroll, Andrew J. ; Devidas, Meenakshi ; Pullen, D. Jeanette ; Payne-Turner, Debbie ; Tasian, Sarah K. ; Reshmi, Shalini ; Cottrell, Catherine E. ; Reaman, Gregory H. ; Bowman, W. Paul ; Carroll, William L. ; Loh, Mignon L. ; Winick, Naomi J. ; Hunger, Stephen P. ; Willman, Cheryl L. / Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia : A Children's Oncology Group Study. In: Blood. 2012 ; Vol. 119, No. 15. pp. 3512-3522.
@article{09897882232341bc8c345e33dedc5559,
title = "Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study",
abstract = "As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5{\%} of cases, only 51.4{\%} of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HRALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.",
author = "Chen, {I. Ming} and Harvey, {Richard C.} and Mullighan, {Charles G.} and Julie Gastier-Foster and Walker Wharton and Huining Kang and Borowitz, {Michael J.} and Camitta, {Bruce M.} and Carroll, {Andrew J.} and Meenakshi Devidas and Pullen, {D. Jeanette} and Debbie Payne-Turner and Tasian, {Sarah K.} and Shalini Reshmi and Cottrell, {Catherine E.} and Reaman, {Gregory H.} and Bowman, {W. Paul} and Carroll, {William L.} and Loh, {Mignon L.} and Winick, {Naomi J.} and Hunger, {Stephen P.} and Willman, {Cheryl L.}",
year = "2012",
month = "4",
day = "12",
doi = "10.1182/blood-2011-11-394221",
language = "English (US)",
volume = "119",
pages = "3512--3522",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia

T2 - A Children's Oncology Group Study

AU - Chen, I. Ming

AU - Harvey, Richard C.

AU - Mullighan, Charles G.

AU - Gastier-Foster, Julie

AU - Wharton, Walker

AU - Kang, Huining

AU - Borowitz, Michael J.

AU - Camitta, Bruce M.

AU - Carroll, Andrew J.

AU - Devidas, Meenakshi

AU - Pullen, D. Jeanette

AU - Payne-Turner, Debbie

AU - Tasian, Sarah K.

AU - Reshmi, Shalini

AU - Cottrell, Catherine E.

AU - Reaman, Gregory H.

AU - Bowman, W. Paul

AU - Carroll, William L.

AU - Loh, Mignon L.

AU - Winick, Naomi J.

AU - Hunger, Stephen P.

AU - Willman, Cheryl L.

PY - 2012/4/12

Y1 - 2012/4/12

N2 - As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HRALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.

AB - As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HRALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.

UR - http://www.scopus.com/inward/record.url?scp=84859820034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859820034&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-11-394221

DO - 10.1182/blood-2011-11-394221

M3 - Article

VL - 119

SP - 3512

EP - 3522

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -